XML 80 R63.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration and License Agreements (Details) € in Millions	1 Months Ended								3 Months Ended	12 Months Ended
	Oct. 31, 2018 USD ($)	Nov. 30, 2017 USD ($)	Oct. 31, 2017 USD ($)	Aug. 31, 2016 USD ($)	Nov. 30, 2015 USD ($) milestone	Oct. 31, 2014 USD ($)	Oct. 31, 2014 EUR (€)	Jul. 31, 2005 USD ($)	Sep. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) job
Collaboration and License Agreements [Abstract]
Sanofi Upfront Payment					$ 300,000,000
Sanofi Development Milestones					$ 110,000,000
Number of development milestones | milestone					4
Sanofi Regulatory Milestones					$ 220,000,000
Number of regulatory milestones | milestone					4
Sanofi Outcomes Study Milestone					$ 100,000,000
Sanofi Sales Milestone Payments					$ 990,000,000
Number of commercial milestones | milestone					6
Royalties percentage					40.00%
Funded commercialization costs					40.00%
Development costs period					3 years
Sanofi Development Costs Funded by Lexicon Maximum Amount					$ 100,000,000
Expiration period					10 years
Sanofi Revenue Allocated to Development Deliverable					$ 113,800,000
Sanofi Revenue Allocated to License Deliverable					126,800,000
Sanofi Revenue Recognized										$ 33,200,000	$ 60,100,000	$ 71,300,000
Sanofi Sales of Clinical Trial Materials											1,900,000	6,300,000
Sanofi Revenue Allocated to Funding Deliverable					$ 59,400,000
Sanofi revenue from filing performance_LXRX										8,600,000
Ipsen Total Payments To Date										45,000,000
Ipsen Total Upfront Payments						$ 24,500,000
Ipsen Milestone Payment Received	$ 1,300,000	$ 3,800,000	$ 3,800,000	$ 6,400,000					$ 5,100,000
Ipsen Revenue Allocated to License Deliverable						21,200,000					1,400,000
Ipsen Maximum Regulatory And Commercial Milestones						11,800,000
Ipsen Revenue Allocated to Development Deliverable						1,700,000
Ipsen Revenue Allocated to Committee Deliverable						$ 100,000
Ipsen Revenue Recognized										4,600,000	16,200,000	$ 7,200,000
Ipsen Royalty Income_LXRX										300,000	100,000
Ipsen product sales										1,600,000	$ 800,000
Ipsen Maximum Sales Milestones | €							€ 72
TIGM Maximum Exposure										14,200,000
TX Enterprise Fund Award								$ 35,000,000
TX Enterprise Fund Award to Texas AM University System								$ 15,000,000
Aggregate number of new jobs | job												1,616
TIGM Per Job Payment Amount										$ 2,415

X

- Definition

Collaboration and License Agreements [Abstract]

+ References

No definition available.

+ Details

Name:	lxrx_CollaborationAndLicenseAgreementsAbstract
Namespace Prefix:	lxrx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenMaximumRegulatoryAndCommercialMilestones
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenMaximumSalesMilestones
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenMilestonePaymentReceived
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenRevenueAllocatedtoLicenseDeliverable
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenRevenueRecognized
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Ipsen Royalty Income_LXRX - represents the royalty income earned during the period from Ipsen's sales of XERMELO in countries outside of the U.S.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenRoyaltyIncome_LXRX
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the total all payments under the agreement to date.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenTotalPaymentsToDate
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenTotalUpfrontPayments
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of product sales to Ipsen.

+ References

No definition available.

+ Details

Name:	lxrx_Ipsenproductsales
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Number Of Positions Created, Inception To Date

+ References

No definition available.

+ Details

Name:	lxrx_NumberOfPositionsCreatedInceptionToDate
Namespace Prefix:	lxrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage

+ References

No definition available.

+ Details

Name:	lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage
Namespace Prefix:	lxrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Research And Development Arrangement, Contract To Perform For Others, Development Costs Period

+ References

No definition available.

+ Details

Name:	lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod
Namespace Prefix:	lxrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Research And Development Arrangement, Contract To Perform For Others, Expiration Period

+ References

No definition available.

+ Details

Name:	lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod
Namespace Prefix:	lxrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones

+ References

No definition available.

+ Details

Name:	lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones
Namespace Prefix:	lxrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones

+ References

No definition available.

+ Details

Name:	lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones
Namespace Prefix:	lxrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones

+ References

No definition available.

+ Details

Name:	lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones
Namespace Prefix:	lxrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage

+ References

No definition available.

+ Details

Name:	lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage
Namespace Prefix:	lxrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the development milestones relating to the achievement of positive results in certain Phase 3 clinical trials in type 2 diabetes patients.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiDevelopmentMilestones
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the milestone based on the results of an outcomes study in type 2 diabetes patients the completion of which would likely occur after initial regulatory approval.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiOutcomesStudyMilestone
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes in each of the United States and Europe.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiRegulatoryMilestones
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the development services deliverable.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the funding deliverable.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiRevenueAllocatedtoFundingDeliverable
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the license deliverable.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiRevenueAllocatedtoLicenseDeliverable
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiRevenueRecognized
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential sales milestones payments under the agreement.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiSalesMilestonePayments
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the sales of clinical trial materials recognized in the period.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiSalesofClinicalTrialMaterials
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the upfront payment under the agreement.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiUpfrontPayment
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Sanofi revenue from filing performance_LXRX - represents revenue earned when Lexicon performed services relating to the filing and application of sotagliflozin to the FDA. Sanofi and Lexicon entered into a contract modification for this specific performance obligation.

+ References

No definition available.

+ Details

Name:	lxrx_Sanofirevenuefromfilingperformance_LXRX
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Under the Texas Enterprise Fund award, Lexicon has a maximum aggregate exposure if Lexicon fails to create the specified number of jobs or obtain credits.

+ References

No definition available.

+ Details

Name:	lxrx_TigmMaximumExposure
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Under the terms of the Texas Enterprise Fund award, subject to certain credits, if Lexicon fails to create the specified number of jobs, the state may require Lexicon to repay $2,415 for each job Lexicon falls short.

+ References

No definition available.

+ Details

Name:	lxrx_TigmPerJobPaymentAmount
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

In July 2005, Lexicon received a $35.0 million award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine using Lexicon's proprietary gene trappying technology, which Lexicon completed in 2007.

+ References

No definition available.

+ Details

Name:	lxrx_TxEnterpriseFundAward
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In July 2005, the Texas Enterprise Fund awarded $15.0 million to the Texas A&M University System for the creation of facilities and infrastructure to house the library.

+ References

No definition available.

+ Details

Name:	lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration